Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$138.37 -1.4%	$141.88	$128.51 ▼ $238.00	$20.25B	0.01	1.30 million shs	1.09 million shs
BLUE bluebird bio	$4.08 +7.7%	$5.53	$3.56 ▼ $28.60	$39.67M	0.76	363,888 shs	2.08 million shs
CRSP CRISPR Therapeutics	$36.99 -2.8%	$43.10	$36.52 ▼ $68.39	$3.26B	1.77	1.55 million shs	1.60 million shs
NVO Novo Nordisk A/S	$69.36 -1.1%	$82.33	$69.18 ▼ $148.15	$311.23B	0.42	5.56 million shs	5.85 million shs
NVS Novartis	$112.69 +1.2%	$107.92	$92.35 ▼ $120.92	$230.34B	0.53	1.49 million shs	2.54 million shs
PFE Pfizer	$25.20 +0.8%	$26.06	$24.48 ▼ $31.54	$142.93B	0.61	39.04 million shs	32.32 million shs
SGMO Sangamo Therapeutics	$0.82 -4.4%	$1.04	$0.30 ▼ $3.18	$184.26M	1.49	7.76 million shs	1.96 million shs
VRTX Vertex Pharmaceuticals	$492.69 -2.0%	$476.45	$377.85 ▼ $519.88	$126.52B	0.41	1.28 million shs	1.28 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	-1.47%	-0.74%	-2.18%	-7.26%	-35.13%
BLUE bluebird bio	+1.07%	-4.29%	-5.72%	-56.83%	-86.12%
CRSP CRISPR Therapeutics	-2.91%	-7.60%	-14.54%	-4.95%	-45.78%
NVO Novo Nordisk A/S	-2.18%	-10.87%	-22.83%	-19.68%	-45.19%
NVS Novartis	+1.25%	-1.67%	+1.58%	+13.28%	+16.25%
PFE Pfizer	-0.56%	-4.26%	-6.37%	-5.89%	-9.79%
SGMO Sangamo Therapeutics	+1.46%	+2.17%	-10.33%	-66.51%	+37.23%
VRTX Vertex Pharmaceuticals	+0.45%	-1.50%	+4.62%	+22.95%	+20.42%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.9108 of 5 stars	4.2	5.0	0.0	3.7	3.4	2.5	1.9
BLUE bluebird bio	2.8662 of 5 stars	3.1	3.0	0.0	0.0	2.5	2.5	1.3
CRSP CRISPR Therapeutics	3.3013 of 5 stars	4.2	2.0	0.0	0.0	2.1	3.3	0.6
NVO Novo Nordisk A/S	4.8113 of 5 stars	4.4	5.0	1.7	0.0	2.4	0.0	4.4
NVS Novartis	3.0286 of 5 stars	1.9	5.0	2.5	0.0	3.4	0.0	1.9
PFE Pfizer	4.9874 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
SGMO Sangamo Therapeutics	2.7273 of 5 stars	4.3	1.0	0.0	0.0	3.3	0.8	0.6
VRTX Vertex Pharmaceuticals	3.8868 of 5 stars	2.3	3.0	0.0	3.3	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.43	Hold	$213.33	54.18% Upside
BLUE bluebird bio	2.25	Hold	$51.00	1,150.00% Upside
CRSP CRISPR Therapeutics	2.48	Hold	$73.11	97.64% Upside
NVO Novo Nordisk A/S	2.80	Moderate Buy	$145.25	109.43% Upside
NVS Novartis	1.80	Reduce	$123.38	9.48% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	26.67% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$5.17	530.08% Upside
VRTX Vertex Pharmaceuticals	2.65	Moderate Buy	$506.70	2.84% Upside

Current Analyst Ratings Breakdown

Latest BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/18/2025	SGMO Sangamo Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$2.00 ➝ $2.00
3/13/2025	NVO Novo Nordisk A/S	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	NVO Novo Nordisk A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/24/2025	BLUE bluebird bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $5.00
2/24/2025	BLUE bluebird bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
2/21/2025	BLUE bluebird bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
2/20/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$407.00 ➝ $408.00
2/19/2025	CRSP CRISPR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.68B	2.09	$22.72 per share	6.09	$114.71 per share	1.21
BLUE bluebird bio	$53.12M	0.75	N/A	N/A	$35.59 per share	0.11
CRSP CRISPR Therapeutics	$35M	90.65	N/A	N/A	$22.52 per share	1.64
NVO Novo Nordisk A/S	$290.40B	1.07	$3.22 per share	21.57	$4.64 per share	14.95
NVS Novartis	$51.72B	4.45	$11.24 per share	10.03	$21.59 per share	5.22
PFE Pfizer	$63.63B	2.25	$3.95 per share	6.38	$15.81 per share	1.59
SGMO Sangamo Therapeutics	$57.80M	3.19	$0.03 per share	30.42	$0.47 per share	1.74
VRTX Vertex Pharmaceuticals	$11.02B	11.48	N/A	N/A	$63.90 per share	7.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$11.19	12.37	8.38	1.51	16.87%	14.98%	8.76%	4/23/2025 (Estimated)
BLUE bluebird bio	-$211.91M	-$37.40	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	5/7/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.37	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	5/6/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.29	21.08	14.88	0.90	34.81%	84.68%	26.29%	5/1/2025 (Estimated)
NVS Novartis	$11.94B	$5.88	19.17	12.79	1.70	23.56%	37.24%	15.85%	4/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.87	8.32	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
SGMO Sangamo Therapeutics	-$257.83M	-$0.52	N/A	N/A	N/A	-257.87%	-264.16%	-107.24%	5/8/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	28.14	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/23/2025	N/A	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
4/22/2025	N/A	NVS Novartis	$2.07	N/A	N/A	N/A	N/A	N/A
3/17/2025	Q4 2024	SGMO Sangamo Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	$11.70 million	$7.55 million
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A
2/11/2025	Q4 2024	CRSP CRISPR Therapeutics	-$1.15	-$0.44	+$0.71	-$0.44	N/A	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/5/2025	Q4 2024	NVO Novo Nordisk A/S	$0.88	$0.91	+$0.03	$0.91	N/A	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/31/2025	Q4 2024	NVS Novartis	$1.80	$1.98	+$0.18	$1.41	$12.86 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NVO Novo Nordisk A/S	$1.57	2.26%	+25.26%	47.72%	N/A
NVS Novartis	$2.51	2.23%	+5.34%	42.69%	N/A
PFE Pfizer	$1.72	6.83%	+2.50%	121.99%	16 Years
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	NVO Novo Nordisk A/S	semi-annual	$0.7874	1.2%	3/31/2025	3/31/2025	4/8/2025
2/20/2025	NVS Novartis		$3.8695		3/12/2025	3/12/2025	3/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
BLUE bluebird bio	0.37	0.51	0.33
CRSP CRISPR Therapeutics	N/A	22.07	22.07
NVO Novo Nordisk A/S	0.62	0.74	0.55
NVS Novartis	0.48	1.04	0.84
PFE Pfizer	0.63	1.00	0.73
SGMO Sangamo Therapeutics	N/A	1.35	1.35
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
BLUE bluebird bio	87.43%
CRSP CRISPR Therapeutics	69.20%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
PFE Pfizer	68.36%
SGMO Sangamo Therapeutics	56.93%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.16%
BLUE bluebird bio	1.40%
CRSP CRISPR Therapeutics	4.10%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
PFE Pfizer	0.06%
SGMO Sangamo Therapeutics	2.80%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
BLUE bluebird bio	520	9.72 million	9.59 million	Optionable
CRSP CRISPR Therapeutics	473	85.77 million	82.26 million	Optionable
NVO Novo Nordisk A/S	54,400	4.49 billion	4.48 billion	Optionable
NVS Novartis	101,700	2.04 billion	2.04 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
SGMO Sangamo Therapeutics	480	224.71 million	202.81 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.79 million	256.28 million	Optionable

BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Headlines

Recent News About These Companies

Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know

March 28 at 10:02 PM | msn.com

Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?

March 28 at 8:28 PM | insidermonkey.com

Vertex Pharmaceuticals (VRTX) Halts VX-264 Development, Incurs $400M Impairment

March 28 at 6:43 PM | gurufocus.com

Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

March 28 at 8:58 AM | benzinga.com

Norges Bank Buys New Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 7:40 AM | marketbeat.com

Loomis Sayles & Co. L P Buys 704,575 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 6:47 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by NEOS Investment Management LLC

March 28 at 6:40 AM | marketbeat.com

Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession

March 28 at 6:30 AM | fool.com

Sava Infond d.o.o. Invests $656,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 6:21 AM | marketbeat.com

Elo Mutual Pension Insurance Co Sells 970 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 6:15 AM | marketbeat.com

Artisan Partners Limited Partnership Buys 114,250 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 6:06 AM | marketbeat.com

Korea Investment CORP Cuts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 5:54 AM | marketbeat.com

LPL Financial LLC Has $76.94 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 28 at 4:32 AM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors

March 27 at 7:05 PM | zacks.com

CSE Bulletin: Consolidation - Vortex Energy Corp. (VRTX)

March 27 at 5:04 PM | newsfilecorp.com

Biopharma firms with foreign exposure face disruption as Trump's tariffs loom

March 27 at 1:20 PM | proactiveinvestors.com

Motley Fool Wealth Management LLC Has $14.73 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 27 at 6:25 AM | marketbeat.com

3,260 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Murphy & Mullick Capital Management Corp

March 27 at 5:50 AM | marketbeat.com

Mitsubishi UFJ Trust & Banking Corp Reduces Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 27 at 5:49 AM | marketbeat.com

595 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by PKS Advisory Services LLC

March 27 at 5:40 AM | marketbeat.com

TD Asset Management Inc. Lowers Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

March 27 at 5:14 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
By Jea Yu | March 10, 2025
View Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Tesla Market Sentiment Sours: Here Are the EV Winners
By Thomas Hughes | March 25, 2025
View Tesla Market Sentiment Sours: Here Are the EV Winners
Chinese Fintech FinVolution: Buy, Sell, or Hold?
By Thomas Hughes | March 24, 2025
View Chinese Fintech FinVolution: Buy, Sell, or Hold?

BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Company Descriptions

Biogen NASDAQ:BIIB

$138.37 -1.96 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$137.85 -0.52 (-0.37%)

As of 07:49 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

bluebird bio NASDAQ:BLUE

$4.08 +0.29 (+7.65%)

Closing price 04:00 PM Eastern

Extended Trading

$4.45 +0.37 (+9.07%)

As of 07:59 PM Eastern

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$36.99 -1.05 (-2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$36.90 -0.09 (-0.24%)

As of 07:57 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Novo Nordisk A/S NYSE:NVO

$69.36 -0.81 (-1.15%)

Closing price 03:59 PM Eastern

Extended Trading

$69.36 +0.01 (+0.01%)

As of 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$112.69 +1.29 (+1.16%)

Closing price 03:59 PM Eastern

Extended Trading

$113.99 +1.30 (+1.15%)

As of 07:52 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)

Closing price 03:59 PM Eastern

Extended Trading

$25.14 -0.07 (-0.26%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sangamo Therapeutics NASDAQ:SGMO

$0.82 -0.04 (-4.35%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 0.00 (-0.24%)

As of 07:55 PM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Vertex Pharmaceuticals NASDAQ:VRTX

$492.69 -9.86 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$488.15 -4.54 (-0.92%)

As of 07:56 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Earnings

Compare Dividends

Latest BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BLUE, SGMO, VRTX, CRSP, NVO, NVS, BIIB, and PFE Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools